Drug intelligence / Profile preview

HU-045

Development stage: Phase 3
Lead developer: Huons Biopharma
Modality: Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

HU-045 is a purified botulinum toxin type A (BoNTA) developed by Huons Biopharma for the treatment of moderate to severe glabellar lines (frown lines). It is designed to reduce the risk of resistance and neutralizing antibody formation by eliminating non-toxin proteins and purifying the neurotoxin protein. The drug acts as a neuromuscular blocking agent, inhibiting acetylcholine release at neuromuscular junctions, thereby reducing muscle activity that causes wrinkles. Clinical trials have demonstrated its safety and efficacy in improving frown lines, with ongoing phase 3 studies in Korea[1][4][5][10].

Other names: IncobotulinumtoxinA

Targets

SNAP25 (Synaptosome-associated protein 25)AChR (Acetylcholine receptor)

Beyond the preview

Go deeper on HU-045.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HU-045.